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Abstract
We previously described the isolation and characterization of three probiotic strains from the feces of exclusively
breast-fed newborn infants: Lactobacillus paracasei CNCM I-4034, Bifidobacterium breve CNCM I-4035 and
Lactobacillus rhamnosus CNCM I-4036. These strains were shown to adhere to intestinal mucus in vitro, to be
sensitive to antibiotics and to resist biliary salts and low pH. In the present study, a multicenter, randomized, double-
blind, placebo-controlled trial with 100 healthy volunteers in three Spanish cities was carried out to evaluate the
tolerance, safety, gut colonization and immunomodulatory effects of these three probiotics. Volunteers underwent a
15-day washout period, after which they were randomly divided into 5 groups that received daily a placebo, a capsule
containing one of the 3 strains or a capsule containing a mixture of two strains for 30 days. The intervention was
followed by another 15-day washout period. Patients did not consume fermented milk for the entire duration of the
study. Gastrointestinal symptoms, defecation frequency and stool consistency were not altered by probiotic intake.
No relevant changes in blood and serum, as well as no adverse events occurred during or after treatment. Probiotic
administration slightly modified bacterial populations in the volunteers’ feces. Intestinal persistence occurred in
volunteers who received L. rhamnosus CNCM I-4036. Administration of B. breve CNCM I-4035 resulted in a
significant increase in fecal secretory IgA content. IL-4 and IL-10 increased, whereas IL-12 decreased in the serum of
volunteers treated with any of the three strains. These results demonstrate that the consumption of these three
bacterial strains was safe and exerted varying degrees of immunomodulatory effects.
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Introduction
The Food and Agriculture Organization (FAO) and the World
Health Organization (WHO) define probiotics as live
microorganisms that confer a health benefit to the host when
administered in adequate amounts [1]. Strains belonging to
Bifidobacterium and Lactobacillus, the predominant and
subdominant groups of the gastrointestinal microbiota,
respectively [2,3], are the most widely used probiotic bacteria
and are included in many functional foods and dietary
supplements [4-6].
The FAO/WHO [1] and the European Union (EU)-funded
Product Safety Enforcement Forum of Europe (EU-PROSAFE)
project [7] have attempted to create consensus guidelines for
probiotic safety evaluation. These groups have recommended
that i) the genus and species of the microorganism must first
be definitively determined by phenotypic and genotypic
techniques, ii) the strains must be deposited in an
internationally recognized culture collection, and iii) the safety
of the bacterial strain must be evaluated through acute
ingestion studies in murine models and the estimation of
potential side effects in human studies.
For probiotics to be successful, they must possess certain
characteristics. The criteria for the selection of probiotics
include tolerance to gastrointestinal conditions (gastric acid and
bile), ability to adhere to the gastrointestinal mucosa and
competitive exclusion of pathogens [8,9].
We have previously described the isolation of three lactic
acid bacteria (LAB) strains from the feces of exclusively breast-
fed newborn infants. These strains were selected based on
their probiotic properties, such as adhesion to intestinal mucus,
sensitivity to antibiotics and resistance to biliary salts and low
pH. We identified these strains as Lactobacillus paracasei
CNCM I-4034, Bifidobacterium breve CNCM I-4035 and
Lactobacillus rhamnosus CNCM I-4036 [10]. In addition, their
safety has been assessed by acute ingestion in
immunocompetent and immunosuppressed BALB/c mouse
models. The three strains inhibited Listeria monocytogenes, the
etiological agent of meningitis, and human rotavirus infections
in vitro [10].
The immunomodulatory effects of probiotics have been
demonstrated in experimental models of allergy, autoimmunity
and inflammatory bowel disease [2]. In the present study, a
multicentric, randomized, double-blind placebo-controlled trial
with healthy volunteers was undertaken to investigate the
tolerance, safety and colonization of the aforementioned
probiotic strains, following the FAO/WHO guidelines [1].
Additionally, we have evaluated their potential
immunomodulatory effects by quantitating cytokines and
secretory IgA in volunteers’ serum and feces, respectively.
Materials and Methods
Ethical statement
All patients enrolled in this study signed an informed consent
form. The study followed the guidelines laid down in the
Declaration of Helsinki and was approved by the ethics review
committees of the University of Granada, Murcia and Valencia.
Probiotics
The probiotic strains Lactobacillus paracasei CNCM I-4034,
Bifidobacterium breve CNCM I-4035 and Lactobacillus
rhamnosus CNCM I-4036 have been described elsewhere [10].
These strains were assayed for enzymatic activity and
carbohydrate utilization, and they were deposited in the
Collection Nationale de Cultures de Microorganismes (CNCM)
of the Institute Pasteur [10].
Experimental design
This study was a multicenter, randomized, double-blind,
placebo-controlled trial. The trial was registered at
www.clinicaltrials.gov as NCT01479543. Randomization was
simple and not subjected to any kind of restriction such as
blocking or block size. One hundred and three healthy
volunteers were enrolled in three different cities in Spain
(Granada, Murcia and Valencia). We used a random allocation
sequence [11]. Briefly, each city was assigned 35 codes taken
from a randomization table. Six codes were assigned to each
treatment in each city. Envelopes containing the codes and
matching those in the randomization table were assigned to
each participant. Volunteers were enrolled and assigned by
Gomez-Llorente C (Granada), Ros G (Murcia) and Corella D
(Valencia). This was a double blind study. A flow chart of the
study design is depicted in Figure 1. The protocol for this trial
and supporting CONSORT checklist are available as
supporting information; see Checklist S1 and Protocol S1.
Volunteers underwent a 15-day washout period (t1), after
which they were randomly and blindly divided into 5 groups that
received daily either a placebo, a capsule containing 9x109
CFUs of one of the 3 strains, or a capsule containing 9x109
CFUs of a mixture of B. breve CNCM I-4035 and L. rhamnosus
CNCM I-4036, for 30 days (t2).
The placebo contained 67% cow’s milk powder, 32.5%
sucrose, and 0.56% vitamin C. The 30-day intervention period
was followed by a second washout of another 15 days (t3)
(Figure 1). Patients did not consume any fermented milk for the
entire duration of the study. Blood samples were taken at t1 and
t2. Blood was centrifuged to separate serum from cells. Fecal
samples were taken at t1, t2 and t3. Baseline data appear in
Table 1.
Volunteers were recruited between July and October 2011.
The first washout was in October 2011. Intervention ended in
November 2011, and the second washout in December 2011.
All determinations were finished by December 2012.
Primary outcome variables were safety, tolerance and
persistence. Secondary outcome variables were bacterial
populations, immunomodulatory effects (cytokine and secretory
IgA production), microbiological analyses, and lymphocyte
populations. Calculation of sample size was done based on the
variance in the main outcome variable persistence, i.e.,
probiotic strain count (log strain CFU/g) in feces and a
difference of 25% compared with the placebo (12). A type 1
error of α=0.05 and a power of 90%, (β=0.1) were assumed.
The calculated minimum number of subjects per group was 19.
The initial number of volunteers per group was as follows:
placebo, n=21; L. paracasei CNCM I-4034, n=21; B. breve
CNCM I-4035, n=20; L. rhamnosus CNCM I-4036, n=21;
Safety and Immune Effects of Three LAB Strains
PLOS ONE | www.plosone.org 2 October 2013 | Volume 8 | Issue 10 | e78111
mixture of B. breve CNCM I-4035 and L. rhamnosus CNCM
I-4036, n=20. One subject each of groups placebo, L.
paracasei CNCM I-4034 and L. rhamnosus CNCM I-4036
voluntarily dropped out of the study. No changes in the
estimated sample size or its precision occurred as all selected
volunteers received intended treatment and were analyzed.
The inclusion criteria were as follows: healthy male or
female, age 18–50 years, normal defecation pattern, blood
parameters within the normal range or not considered clinically
significant if outside of the normal range, BMI 18.0–29.9 kg/m2
and written informed consent. The exclusion criteria were
pregnancy or breast-feeding, blood parameters outside of the
normal range and considered clinically significant, a history of
metabolic or gastrointestinal disease, food allergies, recent use
of antibiotics or laxative drugs, diarrhea, constipation, diabetes
mellitus, smoking and blood pressure > 140/90 mmHg.
Determinations described below were carried out in all
volunteers (20 per group) with the exception of antibiotic
resistance, which was done in Valencia (3 volunteers/group,
n=15).
Collection and preparation of fecal samples
Fecal samples were collected from each volunteer in plastic
pots lined with a sterile plastic bag in anaerobic conditions and
submitted immediately by courier to the laboratory. Samples
were analyzed within a maximum of 4 h.
Gastrointestinal tolerance and safety parameters
Gastrointestinal tolerance was determined using the
gastrointestinal symptom rating scale (GSRS) [13], the King’s
Stool Chart for stool consistency [14], daily recorded
gastrointestinal symptoms (nausea, vomiting, diarrhea,
burping, abdominal distension and flatulence) [15] and
defecation frequency. Baseline GSRS and stool consistency
were measured by the investigator and at 4 and 6 weeks.
Product compliance was recorded daily in a diary. Intolerance
was defined as a symptom score of 2 or higher (moderate or
severe) on the GSRS. Safety parameters were the number and
type of adverse events recorded throughout the entire study
and changes from baseline blood parameters determined at
the end of the supplementation period. The measurement of
blood parameters was performed in the Clinical Analysis
Laboratory of the Virgen de las Nieves Hospital (Granada),
Clinical Hospital (Valencia) and Megalab laboratory (Murcia).
Fluorescence in situ hybridization-flow cytometry
analysis (FISH-FC)
Fecal samples were processed as previously described
[16,17]. One gram of feces was homogenized in 9 mL of PBS
(phosphate-buffered saline), and then 0.2 mL of the
suspension was mixed with 0.6 mL of 4% paraformaldehyde
(PFA) in PBS and fixed overnight at 4°C. Fecal bacterial
populations were assessed by FISH-CF analysis as described
Table 1. Baseline characteristics of the study groups.
 Probiotic groups Placebo group
 (n=80) (n=20)
Sex (male/female) 37/43 9/11
Age (years) 28.7 ± 0.7 28.5 ± 1.7
Height (m) 1.71 ± 0.1 1.7 ± 0.1
Weight (kg) 68.4 ± 1.4 67 ± 2.5
BMI (kg/m2) 23.1 ± 0.4 22.8 ± 0.5
Heart rate (beats/min) 72.0 ± 1.5 71.2 ± 3.0
Blood pressure (mm/Hg)   
Systolic 116.8 ± 1.8 117.6 ± 3.1
Diastolic 71.5 ± 1.2 71.6 ± 2.3
Values are means ± SEM unless otherwise indicated. There were no significant
differences between groups.
doi: 10.1371/journal.pone.0078111.t001
Figure 1.  CONSORT flow diagram of the subjects in the SETOPROB study (NCT01479543).  
doi: 10.1371/journal.pone.0078111.g001
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by Fallani et al. and Gomez-Llorente et al. [16,17]. A panel of
10 group- and species-specific probes covalently linked with
Cy5 at their 5’ end was used to assess the microbiota
composition [18-25] (Table S1).
Hybridization was performed in a 96-well microtiter plate
overnight at 35°C in hybridization solution containing 4 ng/µL of
the appropriate probes, and then 150 µL of hybridization
solution was added to each well. Cells were pelleted and
washed to remove any nonspecific probe binding by incubating
the bacterial cells at 37°C for 20 min in wash solution (64
mmol/L NaCl, 20 mmol/L Tris-HCl, pH 8.0, 5 mmol/L EDTA pH
8.0, 0.01% sodium dodecyl sulfate, pH 7.2). Finally, the cells
were pelleted and resuspended in PBS. Samples were
analyzed in a FACSCanto II flow cytometer (Becton Dickinson,
NJ, USA).
Microbiological analysis
Fecal samples were analyzed by plating appropriate dilutions
onto Wilkins-Chalgren agar (Panreac Quimica, Barcelona,
Spain) to determine the total number of anaerobic bacteria, de
Man-Rogosa-Sharpe (MRS) agar (Oxoid, Basingstoke, United
Kingdom) to determine the number of Lactobacilli, and Beerens
agar (Oxoid, Basingstoke, United Kingdom) to determine the
number of bifidobacteria. The Lactobacillus rhamnosus CNCM
I-4036 count was determined on modified MRS medium in
which glucose was substituted with rhamnose. Only L.
rhamnosus and a few other rare Lactobacillus species in the
human gastrointestinal tract are able to grow on this medium
[12,26].
Antibiotic resistance analysis
The sensitivity of probiotic strains to ampicillin and
tetracycline was analyzed in volunteers’ fecal samples by
plating appropriate dilutions onto MRS agar (Oxoid,
Basingstoke, United Kingdom) supplemented with 0.05% (wt/
vol) cysteine (Sigma-Aldrich) (MRS-C medium) and trypticase
soy agar (TSA, Oxoid) with or without ampicillin (2 and 4
µg/mL; Sigma-Aldrich, St. Louis, MO) or tetracycline (4 and 8
µg/mL; Sigma-Aldrich). The plates were incubated for 48-72 h
at 37°C in an anaerobic atmosphere, which was generated
using an AnaeroGen® system, for MRS and MRS-C, and
aerobically at 30°C in the case of TSA plates.
Isolation procedure
From each patient, 5 to 10 random colonies grown on
modified MRS agar were individually inoculated into MRS broth
medium (Oxoid, Basingstoke, United Kingdom) for 2 days, at
37°C under anaerobic conditions (Anaerogen® Oxoid,
Basingstoke, United Kingdom). DNA was extracted with the
QIAamp DNA Mini Kit (QIAGEN, Barcelona, Spain) and used
for identification by quantitative real-time PCR (qPCR) with
specific primers (see Table S2) for this probiotic strain.
Real-time polymerase chain reaction (PCR)
Real-time PCR was used i) to identify Lactobacillus,
Bifidobacterium spp., Bacteroides and Clostridium difficile in
feces and ii) to confirm intestinal persistence by Lactobacillus
rhamnosus. For the former (i), DNA was isolated from
volunteers’ feces with the QIAamp DNA Stool Mini Kit
(QIAGEN, Barcelona, Spain). For the latter (ii), DNA was
isolated from bacterial cultures (see sections Microbiological
determinations and Re-isolation procedure). The primer
sequences appear in Table S2.
PCR was performed in triplicate in an Eppendorf Mastercycle
EP Gradient. The primer sequences are shown in Table S2
and were purchased from Sigma-Aldrich (Barcelona, Spain).
PCR was carried out using Power SYBR Green Master Mix
(Applied Biosystems, Barcelona, Spain). The PCR program
was as follows: an initial activation/denaturation step at 95°C
for 5 min followed by 30-40 cycles of 15 sec at 95°C, 30-40 sec
for annealing at 55-68°C and a final extension step for 33-45 s
at 72°C. Quantitation was performed using a standard curve.
In the case of strain-specific reactions, PCR was performed
in triplicate in the StepOne Real-Time PCR System (ABI).
Primers were purchased from Thermo Fisher (Thermo Fisher
Scientific, Waltham, MA). PCR was carried out using Power
SYBR Green Master Mix (ABI). Taq polymerase was activated
at 95°C for 10 min. The cycling parameters were denaturation
at 95°C for 15 sec and extension at 64°C for 50 sec (for 30
cycles). Colonies were identified as L. rhamnosus CNCM
I-4036 when amplification appeared.
Determination of the fecal content of secretory IgA
Secretory IgA was analyzed in feces by enzyme-linked
immunosorbant assay (Immundiagnostik AG, Bensheim,
Germany) according to the manufacturer’s instructions.
Preparation and collection of blood samples
Blood samples were collected into BD Vacutainer® tubes
(Becton Dickinson, NJ, USA). An aliquot of the blood was used
for hematological determination. A second aliquot was
centrifuged for 10 min at 1000 x g and 4°C to separate serum
from cells. Serum was collected for cytokine analysis.
Determination of differences in the lymphocyte
population by fluorescence-activated cell sorting
(FACS)
These analyses were performed at the University of Murcia
in the 24-hour period after blood collection to avoid cell lysis.
PerCP-Cy-conjugated anti-human CD14, PE-conjugated anti-
CD4, FITC-conjugated anti-CD4, PE-Cy7 conjugated anti-
CD25, AlexaFluor®-conjugated anti-CD127, PE-conjugated
anti-CD19 and PerCP-conjugated anti-CD8 antibodies
purchased from Becton Dickinson (San Diego, California, USA)
were used to perform multicolor flow cytometric analysis.
The monoclonal antibodies were incubated with 200 µL of
the whole blood samples obtained from volunteers for 15 min
protected from light. Erythrocytes were removed by hypotonic
lysis using Pharm LyseTM (BD Biosciences, San Diego, CA),
and samples were cleaned according to the manufacturer’s
instructions. Flow cytometry was performed using a
fluorescence activated cell sorter (FACS) Calibur® flow
cytometer (Becton Dickinson) and Cell Quest (BD). For each
antibody panel analysis, 2х104 lymphocytes were gated.
Safety and Immune Effects of Three LAB Strains
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Cytokine quantification in serum
IL-4, IL-6, IL-10, IL-12(p70), TNF-α, and TGF-β were
measured using MILLIplexTM immunoassays (Merck-Millipore,
MA, USA) on the Luminex 200 system according to the
manufacturer’s instructions.
Statistical analysis
All results are expressed as the mean ± SEM unless
otherwise indicated. Statistical analyses of gastrointestinal
symptom scores were performed using the Mann–Whitney U
test for equivalence. Time comparisons for normally distributed
parameters were tested for statistical significance by a lineal
model of variance for repeated measures. For those variables
found significantly different, specific time differences were
tested using the paired t test while the paired Wilcoxon test
was used for non-normally distributed parameters. All analyses
were performed using the statistical package IBM SPSS




Of the 103 patients enrolled in the study, 3 dropped out
during the intervention period (Figure 1). Baseline features of
the volunteers appear in Table 1. The average age was 28
years in the placebo and probiotic groups. There was no
significant difference between volunteers who received placebo
and those fed probiotics regarding height, weight, body mass
index, heart rate or blood pressure at baseline.
Tolerance and safety
Symptom scores as measured by the GSRS questionnaire
are described in Table 2. All symptom scores were less than 2,
and there was no significant difference between the control
group and the probiotic-treated group. The median score of the
daily recorded gastrointestinal symptoms of acid regurgitation,
nausea, vomiting, abdominal distension, and eructation did not
change during the probiotic supplementation (intervention) and
subsequent follow-up period. Additionally, the stool consistency
and defecation frequency did not change during the
supplementation period and the subsequent follow-up period in
the probiotic and placebo groups (Table S3)
Therefore, no serious adverse events occurred during the
supplementation period in any of the groups based on the
GSRS questionnaire, which shows that the differences
between the probiotic and placebo groups were not significant
for any of the reported symptoms.
Likewise, no difference between placebo and probiotic
groups occurred in any of the hematological (hemoglobin,
hematocrit, mean corpuscular volume, and leucocyte count)
and biochemical (cholesterol, glucose, AST, ALT, γ-GT, and
creatinine) parameters (Table 3). There was an initial
significant difference in γ-GT between placebo and probiotics
(17.6 ± 1.2 vs. 14.0 ± 0.9 probiotics vs. placebo at t1. P=0.021);
however, such difference in γ-GT remained after the
intervention (17.0 ± 1.1 vs. 13.4 ± 0.8 probiotics vs. placebo at
t2. P=0.011).
All three probiotic strains were found to be sensitive to
ampicillin and tetracycline. In addition, antibiotic sensitivity was
similar among the strains at both t1 and at t2 (Table S4).
Table 2. Gastrointestinal symptom score according to the Gastrointestinal Symptom Rating Scale (GSRS).
      GSRS symptom score      
   Probiotic groups (n=80)   Placebo group (n=20)  
Symptom t1  t2  t3  t1  t2  t3  
 Median Range Median Range Median Range Median Range Median Range Median Range
Abdominal pain (q1) 0  0 0-1 0  0  0  0  
Heartburn (q2) 0  0 0-1 0 0-1 0 0-1 0 0-1 0  
Acid regurgitation (q3) 0 0-1 0 0-1 0 0-1 0  0 0-1 0 0-1
Sucking sensations in the epigastrium (q4) 0  0 0-1 0 0-1 0 0-1 0 0-1 0 0-1
Nausea and vomiting (q5) 0 0-1 0 0-1 0 0-1 0 0-1 0  0  
Borborygmus (q6) 0  0 0-1 0  0  0  0  
Abdominal distension (q7) 0 0-1 0 0-1 0 0-1 0 0-1 0 0-2 0 0-1
Eructation (q8) 0 0-1 0 0-1 0 0-1 0 0-1 0 0-2 0 0-1
Loose stools (q12) 0 0-2 0 0-2 0 0-1 0 0-1 0 0-2 0 0-1
Hard stools (q13) 0 0-2 0 0-2 0 0-1 0 0-1 0 0-2 0 0-1
Urgent need for defecation (q14) 0 0-1 0 0-1 0  0 0-1 0 0-1 0 0-1
Sensation of incomplete evacuation (q15) 0  0  0  0  0  0  
Dyspeptic syndrome (q1-5) 0 0-0.4 0 0-0.8 0 0-0.8 0 0-0.2 0 0.6 0 0.4
Indigestion syndrome (q6-8) 0 0-0.67 0 0-1 0 0-0.67 0 0-0.8 0 0-1 0 0-0.8
Bowel dysfunction syndrome (q12-15) 0 0-1 0 0-1 0 0-0.67 0 0-1 0 0-1 0 0-1
Values are the median and range. q, question number of questionnaire. 0 = absent; 1 = mild; 2 = moderate; 3 = severe. t1, first washout; t2, intervention; t3 , second
washout.
doi: 10.1371/journal.pone.0078111.t002
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Overall, these results indicate that the three probiotic strains
were safe and well tolerated by healthy subjects.
Fecal bacterial populations
FISH and real-time PCR were used to investigate whether
fecal bacterial populations changed due to the various
treatments (Table 4 and Figure 2). The Bifidobacterium genus
and the Atopobium cluster significantly decreased, whereas the
Bacteroides group increased in the feces of the volunteers who
received the placebo. These changes did not occur in any of
the groups fed probiotic strains (Table 4).
A transient increase in the Clostridium coccoides population
occurred at the end of the intervention (t2) in those patients fed
B. breve. However, the percentage of live C. coccoides after
the second washout returned to initial values (t1). The C.
coccoides population significantly increased with L. paracasei
administration after the second washout (Table 4).
The Clostridium leptum population increased in both the
placebo and L. rhamnosus-treated groups. However, the
increase was continuous in the placebo group, whereas the
initial increase in C. leptum slightly but significantly dropped
with L. rhamnosus treatment (Table 4).
Increases in Lactobacillus and Streptococcus groups were
observed in patients fed a mixture of B. breve and L.
rhamnosus. Percentages of live C. difficile and C. perfringens
also increased with administration of the probiotic mixture, but
in this case, both Clostridium spp. remained elevated after the
second washout (t2) (Table 4).
Real-time PCR analysis confirmed the increase in
Bacteroides and the decrease in Bifidobacterium spp. observed
by FISH-FC in the placebo group (Figure 2C and Figure 2E).
Bacteroides also increased upon treatment with the mixture of
B. breve and L. rhamnosus (Figure 2C). Interestingly, C.
Table 3. Volunteers’ hematological and biochemical data.
Parameter Probiotic groups (n=80) Placebo group (n=20)
 t1 t2 t1 t2
Hemoglobin 14.2 ± 0.2 14.1 ± 0.2 14.0 ± 0.3 13.9 ± 0.3
Hematocrit 42.7 ± 0.8 41.4 ± 0.5 41.7 ± 0.9 41.2 ± 1
Mean Corpuscular Volume 88.2 ± 0.5 87.7 ± 0.5 86.5 ± 1.2 86.0 ± 1.1
Leucocytes 6.2 ± 0.1 6.0 ± 0.2 6.4 ± 0.3 6.2 ± 0.4
Total cholesterol 182.4 ± 3.8 182.3 ± 4 180.0 ± 4.6 183.0 ± 7.5
HDL-cholesterol 65.6 ± 1.9 65.0 ± 2 59.0 ± 3 58.0 ± 3.7
LDL-cholesterol 103.1 ± 3.2 104.8 ± 3.6 109.0 ± 3.4 112.0 ± 6.1
Glucose 83.9 ± 0.9 83.4 ± 0.4 85.0 ± 1.8 86.4 ± 1.8
Aspartate transaminase 23.7 ± 1.5 22.3 ± 1.0 25.4 ± 2.1 23.9 ± 1.5
Alanine transaminase 19.1 ± 1.3 21.5 ± 1.2 18.8 ± 1.9 21.1 ± 1.7
γ-glutamyl transferase 17.6 ± 1.2* 17.0 ± 1.1* 14.0 ± 0.9 13.4 ± 0.8
Creatinine 0.8 ± 0.01 0.8 ± 0.02 0.8 ± 0.03 0.8 ± 0.03
Values are means ± SEM. Hemoglobin (g/dL), hematocrit (%), mean corpuscular
volume (fL), leukocytes (x103/µL), total cholesterol (mg/dL), HDL-cholesterol (mg/
dL), LDL-cholesterol (mg/dL), glucose (mg/dL), aspartate transaminase (U/L),
alanine transaminase (U/L), γ-glutamyl transferase (U/L), creatinine (mg/dL).
*P<0.05 probiotic groups vs. placebo; t1, first washout; t2, intervention.
doi: 10.1371/journal.pone.0078111.t003
Table 4. Bacterial populations in healthy volunteers’ fecal
samples by FISH-CF analysis.
Targeted group Capsule  Time (t)  
  t1 t2 t3
 Placebo 9.6 ± 2.3ab 8.7 ± 1.7a 5.8 ± 0.8b
 L. rhamnosus 12.2 ± 2.4 8.3 ± 1.3 9.0 ± 1.3
Bif164 B. breve 6.3 ± 1.3 6.0 ± 1.3 6.8 ± 1.5
 
B. breve plus L.
rhamnosus
8.5 ± 1.8 12.0 ± 3.1 7.2 ± 1.7
 L. paracasei 7.3 ± 1.4 7.3 ± 1.3 8.3 ± 1.5
 Placebo 0.2 ± 0.07 0.7 ± 0.3 0.6 ± 0.2
 L. rhamnosus 1.0 ± 0.3 0.2 ± 0.1 0.3 ± 0.1
Erec482 B. breve 0.2 ± 0.1a 0.5 ± 0.2b 0.2 ± 0.01ac
 
B. breve plus L.
rhamnosus
0.4 ± 0.1 1.0 ± 0.4 0.3 ± 0.2
 L. paracasei 0.3 ± 0.2ab 0.3 ± 0.2a 1.1 ± 0.3b
 Placebo 37.7 ± 3.6ab 39.0 ± 2.4a 44.6 ± 2.7b
 L. rhamnosus 42.2 ± 3.1a 49.3 ± 3.1b 43.0 ± 2.9ab
Clep886 B. breve 44.9 ± 2.6 45.7 ± 3.5 45.5 ± 2.1
 
B. breve plus L.
rhamnosus
52.5 ± 3.4 45.1 ± 2.4 47.0 ± 3.7
 L. paracasei 46.3 ± 2.4 48.7 ± 3.7 48.7 ± 2.7
 Placebo 12.2 ± 2.1a 7.5 ± 1.4b 6.7 ± 1.2bc
 L. rhamnosus 7.9 ± 1.4 7.0 ± 0.9 5.0 ± 0.7
Ato291 B. breve 6.3 ± 1.3 5.4 ± 0.9 5.9 ± 1.0
 
B. breve plus L.
rhamnosus
7.9 ± 2.1 6.1 ± 1.7 6.8 ± 1.5
 L. paracasei 4.2 ± 0.8 5.2 ± 0.8 6.2 ± 0.9
 Placebo 16.6 ± 3.2a 20.7 ± 2.7ab 20.1 ± 2.3b
 L. rhamnosus 14.6 ± 2.0 15.5 ± 2.1 15.7 ± 2.0
Bac303 B. breve 20.4 ± 2.6 20.6 ± 2.6 21.7 ± 2.4
 
B. breve plus L.
rhamnosus
15.8 ± 2.2 13.7 ± 2.1 18.9 ± 2.8
 L. paracasei 17.6 ± 2.0 19.4 ± 2.7 14.1 ± 1.9
 Placebo 0.9 ± 0.2 0.9 ± 0.4 1.4 ± 0.4
 L. rhamnosus 1.8 ± 0.5 1.1 ± 0.3 1.3 ± 0.3
Enter1432 B. breve 1.3 ± 0.4 1.0 ± 0.3 1.3 ± 0.3
 
B. breve plus L.
rhamnosus
1.2 ± 0.4 1.1 ± 0.4 1.2 ± 0.5
 L. paracasei 0.6 ± 0.2 1.3 ± 0.4 1.7 ± 0.5
 Placebo 3.0 ± 0.5 1.8 ± 0.5 2.5 ± 0.4
 L. rhamnosus 2.6 ± 0.5 3.1 ± 0.5 3.6 ± 0.7
Lab158 B. breve 2.9 ± 0.6 2.5 ± 0.5 2.8 ± 0.6
 
B. breve plus L.
rhamnosus
1.8 ± 0.6a 3.2 ± 0.8b 2.6 ± 0.5ab
 L. paracasei 2.2 ± 0.4 3.2 ± 0.6 2.9 ± 0.5
 Placebo 5.5 ± 0.8 4.8 ± 0.7 5.5 ± 0.7
 L. rhamnosus 5.3 ± 0.8 4.7 ± 0.8 5.7 ± 0.7
Strc493 B. breve 5.3 ± 0.7 5.1 ± 0.6 6.1 ± 0.8
 
B. breve plus L.
rhamnosus
3.7 ± 0.8a 5.2 ± 0.7b 5.0 ± 0.7ab
 L. paracasei 3.8 ± 0.6 5.4 ± 0.8 6.2 ± 0.9
 Placebo 6.0 ± 1.0 5.4 ± 0.8 6.4 ± 0.8
 L. rhamnosus 6.8 ± 0.6 7.3 ± 1.2 7.8 ± 1.0
Cdif198 plus
Cperf191
B. breve 7.3 ± 1.1 6.8 ± 0.9 7.3 ± 0.7
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difficile increased in volunteers fed L. rhamnosus immediately
after treatment with this strain ceased (t2) (Figure 2B).
Lactobacillus significantly decreased in the placebo group
after 30 days of intervention and remained low after the second
washout. L. rhamnosus feeding also resulted in a decrease in
Lactobacillus at t2 (Figure 2D).
As for Bifidobacterium spp., this population significantly
decreased in those volunteers who received a daily capsule of
Table 4 (continued).
Targeted group Capsule  Time (t)  
 
B. breve plus L.
rhamnosus
5.5 ± 0.9a 7.3 ± 1.1ab 9.2 ± 0.6b
 L. paracasei 6.2 ± 0.9 6.9 ± 1.0 7.2 ± 0.9
Values are means ± SEM, in percentages of living bacteria. n=20 per group.
Labeled means without a common letter differ. P<0.05. t1, first washout; t2,
intervention; t3, second washout.
doi: 10.1371/journal.pone.0078111.t004
L. rhamnosus when treatment with the probiotic ceased (Figure
2E).
Altogether, these results indicate that both probiotic and
placebo administration modified bacterial populations in the
volunteers’ feces.
Fecal strain persistence
A total of 75 colonies from patients fed L. rhamnosus CNCM
I-4036 were picked from dishes containing MRS modified
medium (glucose substituted with rhamnose) and were
subsequently grown under anaerobic conditions. DNA analysis
by real-time PCR with specific primers for L. rhamnosus CNCM
I-4036 revealed that 86% of the colonies were positive for this
species. This result suggests that at least L. rhamnosus, for
which there is available specific and selective culture medium,
colonized the intestine of volunteers fed this strain for 30 days.
Fecal secretory IgA content
Secretory IgA content was measured in the stools of the
various groups of healthy volunteers (Figure 2A). B. breve
administration resulted in a significant increase in the fecal
Figure 2.  Secretory IgA content (A) and populations of Clostridium difficile (B), Bacteroides (C), Lactobacillus (D), and
Bifidobacterium spp. (E) in the feces of healthy adults fed one daily probiotic capsule or placebo for 4 weeks as log CFU/g
feces.  Values are means ± SEM, n=20 per group. Labeled means without a common letter differ, P<0.05. Time 1, first washout;
Time 2, intervention; Time 3, second washout.
doi: 10.1371/journal.pone.0078111.g002
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secretory IgA content after the 30-day intervention (t2), but this
increase returned to initial values after the second washout (t3).
The secretory IgA content did not change in the feces of
volunteers who received, L. rhamnosus, L. paracasei or the L.
rhamnosus/B. breve mixture.
White blood cell (WBC) subsets
The effects of probiotic administration on various WBC
subsets were analyzed by flow cytometry (Table 5). The most
relevant findings were as follows: i) the significant increases in
the percentage of CD4+ T lymphocytes and CD4+/CD8+ ratio
in the blood of volunteers who received L. paracasei and ii) the
increase in the percentage of regulatory T lymphocytes
observed in the placebo, L. rhamnosus and B. breve groups.
Cytokine concentrations in volunteers’ serum
Serum IL-4, IL-10 and IL-12 concentrations, as well as the
IL-10/IL-12 and TNF-α/IL-10 ratios appear in Figure 3. All
patient groups showed similar values of IL-6, TNF-α and TGF-β
(not shown).
Whereas the anti-inflammatory cytokine IL-4 decreased in
the group fed the placebo for 30 days, the serum concentration
of this cytokine remained unchanged in the groups that
received B. breve, L. paracasei or the combination of both. In
contrast, IL-4 increased in those volunteers fed L. rhamnosus
(Figure 3A). The latter probiotic strain also increased the
concentration of another anti-inflammatory cytokine, IL-10
(Figure 3B).
Volunteers fed the placebo, L. rhamnosus or B. breve
exhibited significantly lower values of the pro-inflammatory
cytokine IL-12 at the end of the intervention (t2) compared with
baseline (t1) (Figure 3C). The IL-10/IL-12 ratio, an anti-
inflammatory index, significantly increased in patients who
received L. rhamnosus and L. paracasei (Figure 3D). In
contrast, L. rhamnosus treatment decreased the TNF-α/IL-10
ratio, a pro-inflammatory index (Figure 3E).
Altogether, these findings point to a clear immunomodulatory
effect of the three probiotic strains, with L. rhamnosus exerting
the most robust effect.
Discussion
In this study, the safety, tolerance, persistence and effects
on the immune system of the probiotic strains Lactobacillus
paracasei CNCM I-4034, Bifidobacterium breve CNCM I-4035
and Lactobacillus rhamnosus CNCM I-4036 [10] were
investigated in 100 healthy volunteers. We found that the
recorded gastrointestinal symptoms (GSRS and daily recorded
symptoms), defecation frequency and stool consistency were
not altered by probiotic intake in healthy volunteers. Moreover,
no relevant changes in blood and serum parameters, and no
adverse events occurred during and after treatment. All three
probiotic strains were sensitive to ampicillin and tetracycline.
Probiotic administration modified bacterial populations in the
volunteers’ feces as evidenced by real-time PCR and
fluorescence in situ hybridization. Some of the alterations were
transient, whereas others were stable. The most relevant
finding regarding bacterial populations was the increase in
Clostridium difficile that took place in feces when L. rhamnosus
CNCM I-4036 administration ceased (t3, Figure 2B), which
points to a clear beneficial effect by this probiotic strain.
Volunteers may have experienced a displacement of C. difficile
by L. rhamnosus CNCM I-4036 during the intervention of 30
days. Many studies have shown a decrease in C. difficile
adhesion to intestinal mucosa by probiotics [27-29].
The fact that total bifidobacteria counts were reduced in the
group treated with B. breve CNCM I-4035 suggests that the
administered strain either did not reach the colon in a viable
state in significant numbers or did not proliferate in the colon.
Table 5. Analysis of immune system populations in
volunteers’ blood.
Subset population Capsule Time (t)
  t1 t2
 Placebo 69.2 ± 1.9 71.4 ± 1.4
 L. rhamnosus 70.8 ± 2.5 72.2 ± 1.4
CD3+(T cells) B. breve 69.6 ± 3.0 70.1 ± 1.8
 B. breve plus L. rhamnosus 74.0 ± 2.5 73.3 ± 2.2
 L. paracasei 70.5 ± 1.9 72.2 ± 1.2
 Placebo 9.6 ± 0.7 9.8 ± 0.8
 L. rhamnosus 10.1 ± 0.5 10.1 ± 0.5
CD19+(B cells) B. breve 9.8 ± 0.7 9.5 ± 0.9
 B. breve plus L. rhamnosus 8.6 ± 0.8 9.6 ± 0.6
 L. paracasei 8.7 ± 0.5 8.8 ± 0.7
 Placebo 45.5 ± 1.9 47.6 ± 1.2
 L. rhamnosus 46.0 ± 2.1 45.7 ± 1.6
CD3+ CD4+ (T helper cells) B. breve 45.4 ± 3.0 47.0 ± 2.3
 B. breve plus L. rhamnosus 49.5 ± 2.0 50.3 ± 2.0
 L. paracasei 43.6 ± 1.7 47.8 ± 1.5*
 Placebo 21.3 ± 1.6 22.5 ± 1.1
 L. rhamnosus 15.8 ± 2.0 20.3 ± 0.7
CD3+ CD8+ (T cytolytic
cells)
B. breve 20.1 ± 1.6 20.4 ± 0.9
 B. breve plus L. rhamnosus 20.4 ± 1.8 19.8 ± 1.4
 L. paracasei 23.4 ± 1.3 22.4 ± 1.1
 Placebo 2.0 ± 0.2 2.2 ± 0.1
 L. rhamnosus 2.1 ± 0.2 2.3 ± 0.1
CD4+/CD8+ cells B. breve 2.1 ± 0.2 2.4 ± 0.2
 B. breve plus L. rhamnosus 2.6 ± 0.2 2.7 ± 0.2
 L. paracasei 1.8 ± 0.1 2.1 ± 0.1*
 Placebo 4.1 ± 0.2 4.9 ± 0.2*
 L. rhamnosus 4.0 ± 0.3 4.9 ± 0.3*
CD3+ CD4+ CD25+ CD127-
(T regulatory cells)
B. breve 3.8 ± 0.3 5.0 ± 0.6*
 B. breve plus L. rhamnosus 4.5 ± 0.4 5.7 ± 0.8
 L. paracasei 4.6 ± 0.2 5.1 ± 0.6
 Placebo 3.1 ± 0.4 4.1 ± 0.5
 L. rhamnosus 3.5 ± 0.4 3.6 ± 0.5
CD14+ B. breve 4.6 ± 0.6 5.3 ± 0.7
 B. breve plus L. rhamnosus 3.6 ± 0.6 3.9 ± 0.4
 L. paracasei 2.8 ± 0.5 3.9 ± 0.6
Results are mean ± SEM, as percentage of total accounted cells. n=20 per group.
*P<0.05. t1, first washout; t2, intervention.
doi: 10.1371/journal.pone.0078111.t005
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Bifidobacteria counts also decreased by L. rhamnosus CNCM
I-4036 feeding when t3 is compared with t1 (Figure 2E).
Strikingly, certain bacterial populations changed in the feces
of volunteers in the placebo group. This effect caused by the
placebo might be due to the cow’s milk and/or sucrose included
in its composition. The fact that regulatory T lymphocytes were
increased in the placebo group is also intriguing. The same is
true for the observation that IL-4 was decreased in the placebo
group. This may indicate that the sample size, while calculated
prior to start of the trial for the main outcome, was too low for
these two variables.
Interestingly, L. rhamnosus CNCM I-4036 was identified after
the intervention (t2) in fecal samples of volunteers that received
this bacterial strain. This finding does not necessarily imply
successful colonization but rather persistence of the strain at
this time period. Detection of L. rhamnosus CNCM I-4036 for a
much longer period would be needed to determine whether the
strain does in fact colonize the gastrointestinal tract. Also, high-
throughput sequencing techniques would be helpful.
Persistence in feces by the two other assayed strains, L.
paracasei CNCM I-4034 and B. breve CNCM I-4035, could not
be proven due to the lack of specific and selective culture
media.
Another interesting finding of this work was that the B. breve
CNCM I-4035 administration resulted in a significant increase
in secretory IgA content after the 30-day intervention. After the
second washout, this increase returned to initial values, which
points to a clear effect due to the probiotic. This result confirms
previous results from our group [10]. We have reported that B.
breve CNCM I-4035 led to a higher IgA concentration in both
feces and plasma of mice [10]. Modification of secretory IgA
has a clear and important effect on the immune system.
Secretory IgA serves as the first line of defense in protecting
the intestinal epithelium from enteric toxins and pathogenic
microorganisms (30). Secretory IgA promotes the clearance of
antigens and pathogenic microorganisms from the intestinal
lumen by blocking their access to epithelial receptors,
entrapping them in mucus, and facilitating their removal by
peristaltic and mucociliary activities [30].
It has been suggested that the safety of probiotics should be
further evaluated by the detection of undesirable changes in
immune parameters [31] because of growing evidence that
probiotics, especially lactobacilli and bifidobacteria, have
Figure 3.  Serum IL-4 (A), IL-10 (B), and IL-12 (C) concentrations and IL-10/TNF-α (D), and IL-10/IL-12 ratios (E) in healthy
adults fed one daily capsule of probiotics or placebo for 4 weeks.  Values are means ± SEM, n=20 per group. Labeled means
without a common letter differ, P<0.05. Time 1, first washout; Time 2, intervention.
doi: 10.1371/journal.pone.0078111.g003
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immunomodulatory properties. The main finding of our cytokine
analysis was that L. paracasei CNCM I-4034, B. breve CNCM
I-4035 and L. rhamnosus CNCM I-4036 exerted
immunomodulatory effects. Increased levels of anti-
inflammatory molecules (IL-4, IL-10, IL-10/IL-12) and
decreased levels of the pro-inflammatory index (TNF-α/IL-10)
were found in the serum of volunteers fed L. rhamnosus CNCM
I-4036. IL-12 also decreased in volunteers that received B.
breve CNCM I-4035, whereas the anti-inflammatory index
(IL-10/IL-12) increased in the group fed L. paracasei CNCM
I-4034. Immunomodulation by these three probiotic strains has
been reported in in vitro experiments by Bermudez-Brito et al.
[32,33]. These authors showed that L. paracasei CNCM I-4034,
B. breve CNCM I-4035 and L. rhamnosus CNCM I-4036
inhibited the production of pro-inflammatory cytokines and
chemokines by human intestinal dendritic cells challenged with
pathogenic bacteria and that such an effect seems to be
mediated through a decreased expression of toll-like receptor
(TLR)-1, TLR-5 and TLR-9 [32,33].
In summary, our results demonstrate that the intake of the
three bacterial strains was safe and exerted a varying degree
of immunomodulatory effects. In particular, L. rhamnosus
CNCM I-4036 colonized the intestine, and B. breve CNCM
I-4035 enhanced production of intestinal secretory IgA. Our
findings also confirm previous results obtained in mice. Overall,
these results warrant further studies and open the possibility of
undertaking similar trials in patients affected by intestinal
pathologies.
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